RxDoctor Payments Data

Richard Clouse, MD

Family Medicine · Glasgow, KYNPI 1720078355

Payments from drug & device makers

$381in general payments, 2019–2025

Across 24 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$194
  • AstraZeneca$38
  • Novo Nordisk$27
  • Novartis$19
  • Amarin Pharma, Inc.$16
  • Pear Therapeutics (US), Inc.$14
  • plus $73 from 6 others

What the payments were for

  • Food & beverage$381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$381 in reported general payments places this provider in the 35th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$64,370
Medicare patients
254
Services billed
889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban782$192,873
JardianceEmpagliflozin93$39,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,366
XareltoRivaroxaban107$20,256
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog90$18,903
FarxigaDapagliflozin Propanediol28$18,417
MyrbetriqMirabegron31$16,473
BrilintaTicagrelor54$16,236
JanuviaSitagliptin Phosphate16$15,586
EntrestoSacubitril/Valsartan116$11,527
Divalproex Sodium188$10,933
VascepaIcosapent Ethyl22$9,040
Fiasp FlextouchInsulin Aspart (Niacinamide)66$8,943
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$7,846
Breo ElliptaFluticasone/Vilanterol19$7,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$38$34,65382 claims
Johnson & JohnsonXarelto$194$20,256107 claims
Astellas Pharma US IncMyrbetriq$12$16,47331 claims
NovartisEntresto$19$11,527116 claims
Novo NordiskNovolog$27$2,63328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →